Shopping Cart
- Remove All
Your shopping cart is currently empty
84-B10 protects against cisplatin-induced acute kidney injury, reversing lipid peroxidation accumulation and downregulation of key ferroptosis inhibitors, inhibiting mitochondrial damage and mtROS production, and restoring superoxide dismutase to reduce cisplatin-induced kidney damage.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $42 | In Stock | |
| 5 mg | $98 | In Stock | |
| 10 mg | $163 | In Stock | |
| 25 mg | $322 | In Stock | |
| 50 mg | $496 | In Stock | |
| 100 mg | $745 | In Stock | |
| 200 mg | $987 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $98 | In Stock |
| Description | 84-B10 protects against cisplatin-induced acute kidney injury, reversing lipid peroxidation accumulation and downregulation of key ferroptosis inhibitors, inhibiting mitochondrial damage and mtROS production, and restoring superoxide dismutase to reduce cisplatin-induced kidney damage. |
| In vitro | 84-B10 (10-100 μM,2 h) inhibited cisplatin induced iron death in renal tubular epithelial cells in a dose-dependent manner. Treatment with 84-B10 (40 μM, 2 hours) restored cisplatin induced mitochondrial structural damage and dysfunction. 84-B10 (40 μM, 2 hours) mitigated MTROS-induced oxidative stress in cisplatin-induced AKI. 84-B10 (40 μM, 2 hours) alleviates cisplatin induced epithelial cell damage by eliminating mtROS and restoring mitochondrial homeostasis [1]. |
| In vivo | 84-B10 plays a protective role in cisplatin induced acute kidney injury, but has no tumor-promoting effect. [1] |
| Molecular Weight | 473.44 |
| Formula | C25H22F3NO5 |
| Cas No. | 698346-43-9 |
| Smiles | O=C(O)CC(C=1C=CC=CC1)CC(=O)NC2=CC(=CC=C2OC3=CC=C(OC)C=C3)C(F)(F)F |
| Color | White |
| Appearance | Solid |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | H2O: < 0.1 mg/mL (insoluble) DMSO: 80 mg/mL (168.98 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.22 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.